Effect of cyclodextrins on α-chymotrypsin stability and loading in PLGA microspheres upon s/o/w encapsulation

Journal of Pharmaceutical Sciences

Volumn 95, Issue 4, 2006, Pages 849-858

  Castellanos, Ingrid J ^a   Flores, Giselle ^a   Griebenow, Kai ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Cyclodextrins; Microspheres; Protein aggregation; Protein stabilization; Solid in oil in water (s o w) encapsulation procedure

Indexed keywords

CHYMOTRYPSIN A; CYCLODEXTRIN DERIVATIVE; DICHLOROMETHANE; HYDROXYL PROPYL BETA CYCLODEXTRIN; METHYL BETA CYCLODEXTRIN; MICROSPHERE; POLYGLACTIN; STABILIZING AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG SOLUBILITY; ENCAPSULATION; ENZYME ACTIVITY; FREEZE DRYING; IN VITRO STUDY; PROTEIN AGGREGATION; PROTEIN STABILITY; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; STATISTICAL ANALYSIS; TECHNIQUE;

EID: 33645961580     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20512     Document Type: Article

References (34)

1. Pérez C, Castellanos IJ, Costantino HR, Al-Azzam W, Griebenow K. 2001. Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. J Pharm Pharmacol 54:301-313.
2. Schwendeman SP. 2002. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 19:73-98.
3. Rodrigues JM Jr, Lima D, Matos CE, Aguiar MM, Cunha AS. 2003. The effect of cyclodextrins on the in vitro and in vivo properties of insulin-loaded poly(D,L-lactic-co-glycolic acid) microspheres. Artif Organs 27:492-497.
4. Aguiar MM, Rodrigues JM Jr, Silva Cunha A. 2004. Encapsulation of insulin-cyclodextrin complex in PLGA microspheres: a new approach for prolonged pulmonary insulin delivery. J Microencapsul 21:553-564.
5. Irie T, Uekama K. 1999. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev 36:101-123.
6. Matsuyama K, El-Gizway S, Perrin JH. 1987. Thermodynamics of binding of aromatic amino acids to α-, β-, and γ-cyclodextrins. Drug Dev Ind Pharm 13:2687-2691.
7. 1H NMR. J Pharm Biomed Anal 29:487-494.
8. Brewster ME, Hora MS, Simpkins JW, Bodor N. 1991. Use of 2-hydroxypropyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm Res 8:792-795.
9. Banga AK, Mitra R. 1993. Minimization of shaking-induced formation of insoluble aggregates of insulin by cyclodextrins. J Drug Target 1:341-345.
10. Charman SA, Mason KL, Charman WN. 1993. Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone. Pharm Res 10:954-962.
11. Tokihiro K, Irie T, Uekama K, Pitha J. 1995. Potential use of maltosyl-β-cyclodextrin for inhibition of insulin self-association in aqueous solution. Pharm Sci 1:49-53.
12. Sharma L, Sharma A. 2001. Influence of cyclodextrin ring substituents on folding-related aggregation of bovine carbonic anhydrase. Eur J Biochem 268:2456-2463.
13. Otzen DE, Knudsen BR, Aachmann F, Larsen KL, Wimmer R. 2002. Structural basis for cyclodextrins' suppression of human growth hormone aggregation. Protein Sci 11:1779-1787.
14. Morlock M, Knoll H, Winter G, Kissel T. 1997. Microenoapsulation of rh-erythropoietin, using biodegradable poly(D,L-lactide-co-glycolide): protein stability and the effects of stabilizing excipients. Eur J Pharm Biopharm 43:29-36.
15. Johansen P, Men Y, Audran R, Corradin G, Merkle HP, Gander B. 1998. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm Res 15:1103-1110.
16. Quaglia F, De Rosa G, Granata E, Ungaro F, Fattal E, La Rotonda MI. 2003. Feeding liquid, non-ionic surfactants and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying. J Control Release 86:267-278.
17. De Rosa G, Larobina D, La Rotonda MI, Musto P, Quaglia F, Ungaro F. 2005. How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/hydroxypropyl-β-cyclodextrin system. J Control Release 102:71-83.
18. Sah H. 1999. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J Control Release 58:143-151.
19. Kang F, Jiang G, Hinderliter A, DeLuca P, Singh J. 2002. Lysozyme stability in primary emulsion for PLGA microsphere preparation: effect of recovery methods and stabilizing excipients. Pharm Res 19:629-633.
20. Kang F, Singh J. 2003. Conformational stability of a model protein (bovine serum albumin) during primary emulsification process of PLGA microspheres synthesis. Int J Pharm 260:149-156.
21. Morita T, Sakamura Y, Harikiri Y, Suzuki T, Yoshino H. 2000. Protein encapsulation into biodegradable microspheres by a novel s/o/w encapsulation method using poly(ethylene glycol) as a protein micronization agent. J Control Release 69:434-444.
22. King TW, Patrick CW. 2000. Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(DL-lactic-co-glycolic acid)/poly (ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique. J Biomed Mater Res 51:383-390.
23. Castellanos IJ, Carrasquillo KG, Lopez JD, Alvarez M, Griebenow K. 2001. Encapsulation of bovine serum albumin in poly(lactide-co-glycolide) microspheres by the solid-in-oil-in-water technique. J Pharm Pharmacol 53:167-178.
24. Castellanos IJ, Cuadrado WL, Griebenow K. 2001. Prevention of structural perturbations and aggregation upon encapsulation of bovine serum albumin into poly(lactide-co-glycolide) microspheres using the solid-in-oil-in-water technique. J Pharm Pharmacol 53:1099-1107.
25. Takada S, Yamagata Y, Misaki M, Taira K, Kurokawa T. 2003. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J Control Release 88:229-242.
26. Castellanos IJ, Cruz G, Crespo R, Griebenow K. 2002. Encapsulation- induced aggregation and loss in activity of γ-chymotrypsin and their prevention. J Control Release 81:307-319.
27. Castellanos IJ, Griebenow K. 2003. Improvement α-chymotrypsin stability upon encapsulation in PLGA microspheres by solvent replacement. Pharm Res 20:1873-1880.
28. Castellanos IJ, Al-Azzam W, Griebenow K. 2005. Effect of the covalent modification with polyethylene glycol on α-chymotrypsin stability upon encapsulation in poly(lactic-co-glycolic) microspheres. J Pharm Sci 94:1-14.
29. Castellanos IJ, Crespo R, Griebenow K. 2003. Poly(ethylene glycol) as stabilizer and emulsifying agent: a novel stabilization approach preventing aggregation and inactivation of proteins upon encapsulation in bioerodible polyester microspheres. J Control Rel 88:135-145.
30. DelMar EG, Laigman C, Brodrick JW, Geokas MC. 1979. A sensitive new substrate for chymotrypsin. Anal Biochem 99:316-320.
31. Griebenow K, Klibanov AM. 1996. On protein denaturation in aqueous-organic but not in pure organic solvents. J Am Chem Soc 118:11695-11700.
32. Griebenow K, Laureano YD, Santos AM, Montañez I, Rodríguez L, Vidal MW, Barletta G. 1999. Improved enzyme activity and enantioselectivity in organic solvents by methyl-β-cyclodextrin. J Am Chem Soc 121:8157-8163.
33. Santos AM, Gónzalez M, Pacheco Y, Griebenow K. 2003. Comparison of theoretical and experimental data to evaluate substrate diffusional limitations for crown ether and methyl-β-cyclodextrin-activated serine protease subtilisin Carlsberg in tetrahydrofuran. Biotechnol Bioeng 84:324-331.
34. Bibby DC, Davies NM, Tucker IG. 2000. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm 197:1-11.